To test whether LINC01134 is specific for chemotherapy in HCC, we did assays for sensitivity to tyrosine kinase inhibitors (TKIs) and found that LINC01134 could also mediate sensitivity to sorafenib (Figures S3C, D). Here, LINC01134 is linked to hepatocellular carcinoma.